Skip to main content

Table 3 Differences in quality of life trajectories between amyloid-positive patients with SCD, MCI, and dementia

From: A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

 

EQ-5D utilities

VAS

Unadjusted

Model 1

Model 2

Unadjusted

Model 1

Model 2

Β (SE)

Β (SE)

Β (SE)

Β (SE)

Β (SE)

Β (SE)

SCD

0.02 (0.02)

0.02 (0.02)

0.001 (0.02)

6.52 (2.15)*

6.45 (2.15)*

4.20 (2.31)

MCI

0.04 (0.02)

0.03 (0.02)

0.02 (0.02)

3.38 (1.93)

3.21 (1.94)

1.51 (2.05)

Dementia

Ref

Ref

Ref

Ref

Ref

Ref

Time * SCD

0.02 (0.005)*

0.02 (0.005)*

0.03 (0.005)*

0.94 (0.54)**

0.95 (0.54)**

0.97 (0.54)**

Time * MCI

0.02 (0.005)*

0.02 (0.005)*

0.02 (0.005)*

1.13 (0.51)*

1.14 (0.51)*

1.14 (0.51)*

Time * dementia

Ref

Ref

Ref

Ref

Ref

Ref

  1. Model 1: adjusted for age, squared age (EQ-5D only), and sex
  2. Model 2: additionally adjusted for comorbidity score, education, and EQ-5D scale (EQ-5D only)
  3. *p < 0.05
  4. **p < 0.10 for interaction term
  5. Of note: main effect of syndrome diagnosis groups represents the average difference between SCD vs. dementia and MCI vs. dementia at baseline; interaction effect represents the difference in QoL over time between SCD vs. dementia and MCI vs. dementia
  6. SCD subjective cognitive decline, MCI mild cognitive impairment, Aβ positive amyloid positive, SE standard error
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193